Datapoints: Trends in naltrexone use among members of a large private health plan.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Psychiatric Services

• Publication date

  2004-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1176/APPI.PS.55.3.221PMID 15001719
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Research to practice: adoption of naltrexone in alcoholism treatment.

  2003cited by this paper
• Understanding US addiction physicians' low rate of naltrexone prescription.

  2003cited by this paper

• Evaluating the antagonist effect of naltrexone implant via opioid challenge tests with escalating doses of hydromorphone injection in former heroin dependent patients

  2025cites this paper
• First-line Medications for the Outpatient Treatment of Alcohol Use Disorder: A Systematic Review of Perceived Barriers

  2021cites this paper
• Organizational Capacity and Readiness to Provide Medication for Individuals with Co-Occurring Alcohol Use Disorders in Public Mental Health Settings

  2021cites this paper
• Attitudes about medications for alcohol use disorder among individuals with serious mental illness: A health belief model analysis.

  2020cites this paper
• Multiple Psychiatric Morbidity and Continued Use of Naltrexone for Alcohol Use Disorder.

  2020cites this paper
• Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON).

  2019cites this paper
• Cannabis Use Disorder Treatment and Reimbursement

  2018cites this paper
• Co-occurring Substance and Mental Health Disorders

  2018cites this paper
• First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario.

  2017cites this paper
• Disparities in pharmacotherapy for alcohol use disorder in the context of universal health care: a Swedish register study

  2017cites this paper
• A Perspective on Opioid Pharmacotherapy: Where We Are and How We Got Here

  2016cites this paper
• Gr upSM Opioid Receptor Antagonists and Alcohol Dependence Treatment PART

  2016cites this paper
• Views about responsibility for alcohol addiction and negative evaluations of naltrexone

  2015cites this paper
• ANTIRELAPSE PHARMACOTHERAPY OF ALCOHOL DEPENDENCE (literature review)

  2014cites this paper
• Medications for Alcohol Use Disorders in a Primary Care Practice-Based Research Network Implementation Study

  2014cites this paper
• Use of naltrexone for alcohol use disorders in the Veterans' Health Administration: a national study.

  2013cites this paper
• The μ-opioid receptor and treatment response to naltrexone.

  2013cites this paper
• Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence.

  2012cites this paper
• Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course.

  2012cites this paper
• Intramuscular extended‐release naltrexone: current evidence

  2011cites this paper
• Open-Label Pilot Study of Extended-Release Naltrexone to Reduce Drinking and Driving Among Repeat Offenders

  2011cites this paper
• Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review.

  2011cites this paper
• Extended-release naltrexone for alcohol dependence: persistence and healthcare costs and utilization.

  2011cites this paper
• Effects of naltrexone treatment for alcohol-related disorders on healthcare costs in an insured population.

  2010cites this paper
• Cost and utilization of extended release naltrexone for alcohol use disorders

  2010influential citation
• Comparison of healthcare utilization among patients treated with alcoholism medications.

  2010cites this paper
• Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector.

  2010cites this paper
• Regular article The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients

  2009cites this paper
• Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients.

  2009influential citation
• The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients.

  2009cites this paper
• Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone.

  2008cites this paper
• Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization.

  2008cites this paper
• Guideline Watch (April 2007): Practice Guideline for the Treatment of Patients With Substance Use Disorders, 2nd Edition

  2007cites this paper
• Efficacy of Extended-Release Naltrexone in Alcohol-Dependent Patients Who Are Abstinent Before Treatment

  2007cites this paper
• The BRENDA Model: Integrating Psychosocial Treatment and Pharmacotherapy for the Treatment of Alcohol Use Disorders

  2006cites this paper
• Guideline for Physicians Working in California Opioid Treatment Programs

  2005cites this paper
• Naltrexone: clinical data

  2005cites this paper
• Annals of the New York Academy of Sciences a Pharmaceutical Industry Perspective on the Economics of Treatments for Alcohol and Opioid Use Disorders

  year unknowncites this paper